Lawsuit Alleges Actos Bladder Cancer Death Could Have Been Avoided
In an Actos bladder cancer lawsuit filed on March 15, 2012 in the Cook County Circuit Court of Illinois, Ohio resident Jeanette Hare says her husband’s death of bladder cancer could have been avoided if Takeda Pharmaceuticals had properly warned the public about the risks of taking the diabetes drug Actos.
Approved by the Food and Drug Administration (FDA) in 1999, type II diabetes patients use Actos (pioglitazone) to help regulate their blood sugar. Unfortunately, the drug has been linked to several serious side effects, including Actos heart failure and bladder cancer .
Hare hired an Actos lawyer after her husband, George Hare, died of complications related to bladder cancer on March 15, 2010. At the time of his death, George Hare was taking Actos to help manage symptoms associated with type II diabetes.
Actos lawyer alleges failure to warn
Hare’s Actos lawyer seeks to obtain compensation for the losses she incurred as a result of her husband’s death. In her Actos lawsuit, Hare alleges that Takeda knew Actos cancer was a possibility before it was approved by the FDA. According to her Actos lawyer, a two-year carcinogenicity study that was conducted before FDA approval, showed that the drug caused tumors in the urinary bladders of rats.
Takeda did not report this information and in 2005, Takeda executives dismissed a PROactive study that showed those taking Actos were at a significantly greater risk of developing bladder cancer than those taking other drugs to treat type II diabetes.
FDA Intervenes with Actos cancer
On September 17, 2010, the FDA announced a safety warning regarding Actos bladder cancer. After reviewing a 10-year Kaiser Permanente study linking Actos use to bladder cancer, the regulatory agency decided to alert consumers to information showing that the risk of bladder cancer increased significantly if used for more than 24 months.
On June 15, 2011, the FDA issued another safety announcement requiring Takeda to place Actos bladder warnings and precautions on the drug’s label. According to the FDA, those who are exposed to Actos for more than 12 months are at a 40 percent greater risk of developing Actos cancer than those who do not.
Hare says that if Takeda had done its due diligence and warned consumers about the risk of developing Actos cancer, her husband’s death could have been avoided.